Carol Satler, M.D, PhD, is a seasoned physician executive with over 20 years of success in clinical development across high-growth, innovative companies. Her extensive career spans roles at Pfizer, ...
Approvable population of ulcerative colitis (UC) patients for upcoming Phase 3 trials agreed upon with the U.S. Food and Drug Administration (FDA) Analysis of Phase 2 data using approvable UC patient ...
Oruka Therapeutics, Inc. announced progress in its clinical programs with ORKA-001 and ORKA-002, targeting chronic skin diseases like psoriasis. The company completed dosing in a Phase 1 trial for ...
YD Bio Limited ('YD Bio” or the 'Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer ...
Rapid enrollment in Phase 2 portions of the ARROS-1 and ALKOVE-1 clinical trials; Pivotal data from both ROS1 and ALK programs now anticipated in 2025 Initiation of ALKAZAR Phase 3 randomized, ...
Welcome to the Regeneron conference call to discuss its Factor XI development program. My name is Shannon, and I will be your operator for today's call. [Operator Instructions] Please note that this ...
Clinical trials rely heavily on robust data collection and management processes to ensure scientific validity and regulatory compliance. While case report forms (CRFs) have traditionally been the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback